 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 1.6 hours |
| Excretion | renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.124.957 |
| Chemical and physical data | |
| Formula | C12H15N |
| Molar mass | 173.259 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Bicifadine (DOV-220,075) is aserotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered atAmerican Cyanamid as ananalgesic drug candidate, and licensed toDOV Pharmaceutical in 1998 after American Cyanamid was acquired byWyeth.[1][2][3]
In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain.[4][5][6] XTL ran a PhaseIIb clinical trial for pain caused bydiabetic neuropathy, which failed in 2008;[7] XTL terminated the agreement in 2010.[8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.[9]
Bicifadine has a non-opioid, non-NSAIDmechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.[10] While the drug is purported to be aserotonin (SERT) andnoradrenaline transporter (NET) inhibitor, it also has effects at thedopamine transporter (DAT), effectively making it a broad-spectrummonoamine transporter inhibitor or "triple reuptake inhibitor."[11]